alagebrium has been researched along with thiazoles in 80 studies
Studies (alagebrium) | Trials (alagebrium) | Recent Studies (post-2010) (alagebrium) | Studies (thiazoles) | Trials (thiazoles) | Recent Studies (post-2010) (thiazoles) |
---|---|---|---|---|---|
83 | 10 | 31 | 33,179 | 2,100 | 12,330 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 47 (58.75) | 29.6817 |
2010's | 29 (36.25) | 24.3611 |
2020's | 4 (5.00) | 2.80 |
Authors | Studies |
---|---|
Asif, M; Brines, M; Cerami, A; Egan, J; Jyothirmayi, GN; Lopez, S; Masurekar, MR; Regan, TJ; Torres, RL; Ulrich, P; Vasan, S; Wagle, D; Williams, C | 1 |
Grill, V; Hiramatsu, S; Inoue, K; Tajirl, Y | 1 |
Melton, L | 1 |
Brines, M; Cerami, A; Egan, JJ; Ingram, DK; Lakatta, EG; Lane, M; Roth, GS; Spurgeon, H; Ulrich, P; Vaitkevicius, PV; Vasan, S; Wagle, DR; Wuerth, JP | 1 |
Cerami, A; Ulrich, P | 1 |
Doggrell, SA | 1 |
Capriotti, AR; deGroof, RC; Kass, DA; Kawaguchi, M; Lakatta, EG; Scuteri, A; Shapiro, EP | 1 |
Hendriks, M; Levels, AA; Mentink, CJ; Wolffenbuttel, BH | 1 |
Kawakami, M; Kuroki, M | 1 |
Burns, WC; Burrell, LM; Candido, R; Cooper, ME; Dean, RG; Forbes, JM; Ritchie, RH; Thallas, V; Thomas, MC; Tikellis, C; Twigg, SM | 1 |
Kass, DA | 1 |
Jyothirmayi, GN; Liu, J; Malhotra, A; Masurekar, MR; Meggs, LG; Regan, TJ; Vatner, DE; Vatner, SF | 1 |
Burns, WC; Cooper, ME; Forbes, JM; Founds, HW; Jerums, G; Thallas, V; Thomas, MC | 1 |
Cooper, M; Forbes, J; Jerums, G; Osicka, T; Panagiotopoulos, S | 1 |
Foiles, P; Founds, H; Vasan, S | 1 |
Ahn, J; Frohlich, ED; Susic, D; Varagic, J | 2 |
Allen, TJ; Burns, WC; Candido, R; Cooper, ME; Deemer, EK; Forbes, JM; Jandeleit-Dahm, KA; Lassila, M; Thallas, V; Thomas, MC; Thorpe, SM; Thorpe, SR; Yee, LT | 1 |
Allen, TJ; Burns, WC; Calkin, AC; Candido, R; Cooper, ME; Forbes, JM; Jandeleit-Dahm, KA; Lassila, M; Seah, KK; Thallas, V; Thomas, MC | 1 |
Bach, LA; Boner, G; Cooper, ME; Forbes, JM; Haller, H; Lindschau, C; Meier, M; Rizkalla, B; Thallas-Bonke, V | 1 |
Bakris, GL; Bank, AJ; Kass, DA; Neutel, JM; Oparil, S; Preston, RA | 1 |
Cooper, ME | 1 |
Degroof, RC; Hundley, WG; Kitzman, DW; Little, WC; O'Brien, TX; Zile, MR | 1 |
Redfield, MM | 1 |
Tuttle, KR; Williams, ME | 1 |
Cui, H; Li, S; Wang, LL; Zhong, W | 1 |
Imaizumi, T; Yamagishi, S | 1 |
Nakamura, J | 1 |
Allen, TJ; Jandeleit-Dahm, KA; Lassila, M | 1 |
Bivalacqua, TJ; Cellek, S; Foxwell, NA; Gur, S; Hellstrom, WJ; Kendirci, M; Usta, MF | 1 |
O'Rourke, MF | 1 |
Basgen, J; Brem, H; Cai, W; Li, Z; Peppa, M; Uribarri, J; Vlassara, H; Zhang, JG | 1 |
Cooper, ME; Soldatos, G | 1 |
Arnstein, M; Cooper, ME; Coughlan, MT; Forbes, JM; Gasser, A; Long, DM; Pete, J; Thallas-Bonke, V; Thorpe, SR; Tong, DC | 1 |
Scuteri, A | 1 |
Capriotti, A; Clattenburg, L; Corretti, MC; Gerstenblith, G; Kass, DA; Melenovsky, V; Zieman, SJ | 1 |
Chin-Dusting, JP; Cooper, ME; Coughlan, MT; Forbes, JM; Hoang, A; Murphy, AJ; O'Brien, R; Sviridov, D; Thomas, MC | 1 |
Cooper, ME; Coughlan, MT; Forbes, JM | 1 |
Gangula, PR; Jeyabal, PV; Kumar, R; Micci, MA; Pasricha, PJ | 1 |
Barter, PJ; Brown, BE; Davies, MJ; Nobécourt, E; Rye, KA; Yadav, S; Zeng, J | 1 |
Cooper, ME; Forbes, JM; Sourris, KC | 1 |
Bialkowski, K; Bierhaus, A; Cooper, ME; Coughlan, MT; Forbes, JM; Harcourt, BE; Pete, J; Tan, A; Thomas, MC; Tikellis, C | 1 |
Meyer, DM; Mills, LD; Mohammed, SF; Owan, TE; Redfield, MM; Schalkwijk, CG; Shapiro, BP | 1 |
Hartog, JW; Voors, AA; Willemsen, S | 1 |
Cheng, YL; Guo, Y; Lu, M; Qian, J | 1 |
Desai, KM; Dhar, A; Wu, L | 1 |
Andrikopoulos, S; Bierhaus, A; Cooper, ME; Coughlan, MT; Forbes, JM; Harcourt, BE; O'Brien, RC; Penfold, S; Sourris, KC; Tan, AL; Thallas-Bonke, V; Thomas, MC | 1 |
Hartog, JW; Hummel, YM; Posma, JL; van Veldhuisen, DJ; van Wijk, LM; Voors, AA; Willemsen, S | 1 |
Gabelt, BT; Kaufman, PL; Kiland, JA; Lütjen-Drecoll, E; Tezel, G | 1 |
Ferrucci, L; Nicklett, EJ; Semba, RD | 1 |
Andrikopoulos, S; Bierhaus, A; Chand, V; Cooper, ME; Coughlan, MT; de Courten, B; de Courten, MP; Dougherty, SL; Forbes, JM; Harcourt, BE; Kingwell, BA; Morley, AL; Penfold, SA; Sourris, KC; Thallas-Bonke, V; Thomas, MC; Walker, KZ | 1 |
Choi, WJ; Ha, H; Huh, JY; Jeong, LS; Kim, J; Kim, WY; Kwon, MK; Lee, GT; Lee, HB; Nagai, R; Park, J | 1 |
Forbes, J; Griffith, R; Horne, S; Krautwald, M; Leech, D; Münch, G; Rahmadi, A; Steele, ML | 1 |
Hartog, JW; Hillege, HL; Hummel, YM; Posma, JL; van Veldhuisen, DJ; van Wijk, LM; Voors, AA; Willemsen, S | 1 |
Fassot, C; Freidja, ML; Henrion, D; Loufrani, L; Tarhouni, K; Toutain, B | 1 |
Barodka, V; Benjo, AM; Berkowitz, DE; Daher, JP; Gupta, G; Levine, BD; Lussman, C; Nyhan, SM; Pellakuru, L; Ryoo, S; Shoukas, AA; Steppan, J; Tran, H; White, AR | 1 |
Bierhaus, A; Cooper, ME; Gray, SP; Jandeleit-Dahm, KA; Jiaze, L; Pickering, R; Soro-Paavonen, A; Thomas, MC; Tikellis, C; Tsorotes, D; Watson, AM; Wong, B | 1 |
Bugatti, S; Damman, K; Hartog, JW; Hummel, YM; Metra, M; Sipkens, JS; van Veldhuisen, DJ; Voors, AA; Willemsen, S | 1 |
Yamagishi, S | 1 |
Engelen, L; Schalkwijk, CG; Stehouwer, CD | 1 |
Abdullah, SM; Adams-Huet, B; Barkley, KW; Bhella, PS; Boyd, KN; Carrick-Ranson, G; Fujimoto, N; Hastings, JL; Levine, BD; Livingston, SA; Palmer, D; Shafer, KM; Shibata, S | 1 |
Hopman, MT; Levine, BD; Olde Rikkert, MG; Oudegeest-Sander, MH; Smits, P; Thijssen, DH; van Dijk, AP | 1 |
Desai, KM; Dhar, A; Dhar, I; Wu, L | 1 |
Gao, Z; Guan, R; Li, G; Li, H; Tian, W; Uwais, Z; Wang, L; Xin, Z | 1 |
Chen, W; Cheng, X; Cui, H; He, K; Li, S; Wang, L; Zhang, B; Zhong, W | 1 |
Kyriazis, M | 1 |
André-Frei, V; Bechetoille, N; Berthod, F; Cadau, S; Leoty-Okombi, S; Pain, S | 1 |
Kersten, JR; LaDisa, JF; Passerini, AG; Rajamani, A; Schrepfer, S; Toth, JM; Wang, H; Weihrauch, D | 1 |
Chan, DC; Chiang, CK; Chiu, CY; Liu, SH; Sheu, ML; Tsai, KS; Yang, RS; Yang, TH | 1 |
Bhat, A; Desai, KM; Dhar, A; Dhar, I | 1 |
Atlı, Ö; Burukoğlu, D; Ergun, B; Ilgın, S; Musmul, A; Sırmagül, B | 1 |
Borg, DJ; Forbes, JM | 1 |
Boyd, K; Carrick-Ranson, G; Fujimoto, N; Hastings, JL; Levine, BD; Palmer, MD; Shafer, KM; Shibata, S | 1 |
Babu, MS; Bhat, A; Desai, KM; Dhar, A; Dhar, I; Kalra, J; Malapati, P; Medapi, B; Sriram, D; Udumula, MP | 1 |
Chao, TF; Chen, YJ; Kao, YH; Lee, TI; Lee, TW | 1 |
Allen, MR; Avin, KG; Chen, NX; Creecy, A; Metzger, CE; Moe, SM; Nickolas, TL; O'Neill, K; Srinivasan, S; Wallace, JM | 1 |
Qi, L; Wang, R; Yu, HZ | 1 |
Feng, B; Li, Z; Yang, P | 1 |
Ender Caylan, A; Gurbuz, N; Gurkan, R; Surmen Usta, S; Usta, MF | 1 |
22 review(s) available for alagebrium and thiazoles
Article | Year |
---|---|
Protein glycation, diabetes, and aging.
Topics: Aging; Animals; Diabetes Mellitus; Glycation End Products, Advanced; Humans; Models, Chemical; Thiazoles | 2001 |
ALT-711 decreases cardiovascular stiffness and has potential in diabetes, hypertension and heart failure.
Topics: Animals; Diabetes Mellitus; Heart Failure; Humans; Hypertension; Thiazoles | 2001 |
[Aminoguanidine and other AGE inhibitors].
Topics: Amides; Animals; Arteriosclerosis; Cardiovascular Diseases; Cataract; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Retinopathy; Disease Models, Animal; Drug Design; Glycation End Products, Advanced; Guanidines; Humans; Hydrazines; Hypoglycemic Agents; Thiadiazoles; Thiazoles; Thiazolidines | 2002 |
Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Enzyme Inhibitors; Forecasting; Glycation End Products, Advanced; Guanidines; Humans; Protein Kinase C; Ramipril; Renin-Angiotensin System; Thiazoles | 2003 |
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks.
Topics: Aging; Animals; Clinical Trials as Topic; Cross-Linking Reagents; Diabetes Mellitus; Diastole; Drug Evaluation, Preclinical; Elasticity; Glycation End Products, Advanced; Guanidines; Humans; Hypertrophy, Left Ventricular; Molecular Structure; Myocardium; Proteins; Skin; Thiazoles | 2003 |
Crosslink breakers: a new approach to cardiovascular therapy.
Topics: Aging; Animals; Blood Pressure; Cardiovascular Diseases; Collagen; Comorbidity; Cross-Linking Reagents; Diabetes Mellitus; Glycation End Products, Advanced; Humans; Hypertension; Kidney Failure, Chronic; Rats; Thiazoles; Treatment Outcome | 2004 |
Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.
Topics: Aging; Animals; Blood Pressure; Blood Vessels; Cardiovascular Agents; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Glycation End Products, Advanced; Heart Failure; Humans; Hypertension; Thiazoles | 2004 |
Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease.
Topics: Animals; Atherosclerosis; Blood Glucose; Cardiomyopathies; Cardiovascular Agents; Diabetic Angiopathies; Diabetic Nephropathies; Fibrosis; Glycation End Products, Advanced; Humans; Myocardium; Thiazoles | 2004 |
Treating diastolic heart failure with AGE crosslink breakers: thinking outside the heart failure box.
Topics: Animals; Clinical Trials as Topic; Collagen; Drug Evaluation, Preclinical; Glycation End Products, Advanced; Heart Failure; Humans; Thiazoles; Ventricular Dysfunction, Left | 2005 |
The next generation of diabetic nephropathy therapies: an update.
Topics: Animals; Diabetic Nephropathies; Disease Progression; Enzyme Inhibitors; Glycation End Products, Advanced; Glycosaminoglycans; Humans; Indoles; Maleimides; Models, Animal; Protein Kinase C; Pyridoxamine; Renal Agents; Thiazoles | 2005 |
[Targeted AGEes and AGEs cross-link in drug discovery: preventing and reversing arterial sclerosis in aging and diabetes].
Topics: Aging; Animals; Arteries; Arteriosclerosis; Blood Pressure; Diabetes Mellitus; Glycation End Products, Advanced; Guanidines; Humans; Thiazoles | 2005 |
[Progress on the drug therapy for diabetic microangiopathies: AGE inhibitors].
Topics: Animals; Clinical Trials as Topic; Depression, Chemical; Diabetic Angiopathies; Glycation End Products, Advanced; Guanidines; Humans; Oxidative Stress; Pyridoxamine; Thiadiazoles; Thiamine; Thiazoles; Thiazolidines | 2005 |
[Development of therapeutic agents for diabetic neuropathies].
Topics: Aldehyde Reductase; Antioxidants; C-Peptide; Diabetic Neuropathies; Drug Design; Enzyme Inhibitors; Genetic Therapy; Glycation End Products, Advanced; Hedgehog Proteins; Humans; Indoles; Maleimides; Nerve Growth Factor; Oxidative Stress; Polymers; Protein Kinase C; Rhodanine; Thiadiazoles; Thiamine; Thiazoles; Thiazolidines; Trans-Activators; Vascular Endothelial Growth Factor A | 2005 |
Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies.
Topics: Amides; Animals; Arteriosclerosis; Diabetic Angiopathies; Diabetic Nephropathies; Glycation End Products, Advanced; Humans; Hydrazines; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Thiazoles | 2005 |
Advanced glycation end products and vascular structure and function.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelium, Vascular; Glycation End Products, Advanced; Humans; Lymphocyte Activation; Receptor for Advanced Glycation End Products; Thiazoles | 2006 |
Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; Glycation End Products, Advanced; Humans; Isoenzymes; Protein Kinase C; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Renin-Angiotensin System; Thiazoles | 2007 |
Therapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome?
Topics: Carnosine; Diabetes Complications; Diabetic Neuropathies; Glycation End Products, Advanced; Humans; Reactive Oxygen Species; Thiazoles | 2008 |
Does accumulation of advanced glycation end products contribute to the aging phenotype?
Topics: Aging; Bone and Bones; Brain; Diet; Enzyme Inhibitors; Erythrocytes; Eye; Food Analysis; Glycation End Products, Advanced; Guanidines; Humans; Inflammation; Kidney; Liver; Longevity; Muscle, Skeletal; Myocardium; Oxidative Stress; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Tendons; Thiazoles | 2010 |
Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders.
Topics: Aging; Animals; Cross-Linking Reagents; Diabetes Complications; Glycation End Products, Advanced; Humans; Thiazoles | 2012 |
Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Enzyme Inhibitors; Evidence-Based Medicine; Female; Glycation End Products, Advanced; Guanidines; Humans; Hyperglycemia; Male; Pyridoxamine; Thiamine; Thiazoles; Treatment Outcome | 2013 |
Targeting advanced glycation with pharmaceutical agents: where are we now?
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus; Glycation End Products, Advanced; Humans; Maillard Reaction; Thiazoles | 2016 |
Therapeutic potential of vitamin D in AGE/RAGE-related cardiovascular diseases.
Topics: Actin Cytoskeleton; Animals; Calcium; Cardiotonic Agents; Diabetic Cardiomyopathies; Gene Expression Regulation; Glycation End Products, Advanced; Guanidines; Humans; Myocardial Reperfusion Injury; Myocarditis; Oxidative Stress; Receptor for Advanced Glycation End Products; Signal Transduction; Thiazoles; Vascular Stiffness; Vitamin D | 2019 |
10 trial(s) available for alagebrium and thiazoles
Article | Year |
---|---|
Improved arterial compliance by a novel advanced glycation end-product crosslink breaker.
Topics: Aged; Arteries; Blood Pressure; Cardiac Output; Compliance; Double-Blind Method; Drug Tolerance; Elasticity; Female; Forecasting; Glycation End Products, Advanced; Humans; Male; Middle Aged; Thiazoles | 2001 |
The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure.
Topics: Aged; Aorta; Blood Flow Velocity; Blood Pressure; Echocardiography; Exercise Test; Female; Glycation End Products, Advanced; Heart Failure; Humans; Magnetic Resonance Imaging; Male; Oxygen Consumption; Prospective Studies; Quality of Life; Surveys and Questionnaires; Thiazoles; Ventricular Dysfunction, Left | 2005 |
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.
Topics: Aged; Aging; Blood Pressure; Carotid Arteries; Collagen; Elasticity; Endothelium, Vascular; Female; Glycation End Products, Advanced; Humans; Hypertension; Intercellular Adhesion Molecule-1; Male; Manometry; Matrix Metalloproteinase 9; Middle Aged; Peripheral Vascular Diseases; Single-Blind Method; Thiazoles; Transforming Growth Factor beta1; Vascular Cell Adhesion Molecule-1; Vasodilation | 2007 |
Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial.
Topics: Diastole; Double-Blind Method; Echocardiography, Stress; Exercise Test; Exercise Tolerance; Female; Glycation End Products, Advanced; Health Status Indicators; Heart Failure; Humans; Male; Middle Aged; Oxygen Consumption; Research Design; Stroke Volume; Surveys and Questionnaires; Systole; Thiazoles; Ventricular Function, Left | 2010 |
Targeted reduction of advanced glycation improves renal function in obesity.
Topics: Adolescent; Adult; Animals; Cross-Over Studies; Diet; Glycation End Products, Advanced; Humans; Inflammation; Kidney; Kidney Diseases; Male; Mice; Mice, Knockout; Middle Aged; Obesity; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Thiazoles; Young Adult | 2011 |
Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.
Topics: Aged; Cardiovascular Agents; Chronic Disease; Diagnostic Techniques, Cardiovascular; Double-Blind Method; Exercise Tolerance; Female; Glycation End Products, Advanced; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Thiazoles | 2011 |
Functional and hemodynamic cardiac determinants of exercise capacity in patients with systolic heart failure.
Topics: Age Factors; Aged; Analysis of Variance; Cardiac Output; Chi-Square Distribution; Double-Blind Method; Exercise Test; Exercise Tolerance; Heart Failure, Systolic; Heart Rate; Hemodynamics; Humans; Linear Models; Male; Middle Aged; Predictive Value of Tests; Prognosis; Prospective Studies; Risk Assessment; Sex Factors; Stroke Volume; Survival Rate; Thiazoles | 2012 |
Cardiovascular effects of 1 year of alagebrium and endurance exercise training in healthy older individuals.
Topics: Aged; Aged, 80 and over; Aging; Cardiovascular System; Dose-Response Relationship, Drug; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Follow-Up Studies; Heart Ventricles; Humans; Male; Middle Aged; Prospective Studies; Reference Values; Thiazoles; Time Factors; Ventricular Function, Left | 2013 |
The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial.
Topics: Age Factors; Aged; Aging; Blood Flow Velocity; Cardiovascular Diseases; Endothelium, Vascular; Exercise Test; Exercise Therapy; Female; Glycation End Products, Advanced; Humans; Male; Oxygen Consumption; Physical Fitness; Plethysmography; Pulse Wave Analysis; Risk Assessment; Risk Factors; Sedentary Behavior; Thiazoles; Time Factors; Treatment Outcome; Vascular Stiffness; Vasoconstriction; Vasodilation | 2013 |
The effect of 1 year of Alagebrium and moderate-intensity exercise training on left ventricular function during exercise in seniors: a randomized controlled trial.
Topics: Aged; Combined Modality Therapy; Exercise; Exercise Therapy; Female; Humans; Male; Oxygen Consumption; Risk Reduction Behavior; Sedentary Behavior; Thiazoles; Treatment Outcome; Ventricular Function, Left | 2016 |
48 other study(ies) available for alagebrium and thiazoles
Article | Year |
---|---|
An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.
Topics: Aging; Animals; Diastole; Dogs; Elasticity; Glycation End Products, Advanced; Heart Rate; Hemodynamics; Male; Myocardium; Stroke Volume; Systole; Thiazoles; Ventricular Function | 2000 |
Improvement by aminoguanidine of insulin secretion from pancreatic islets grafted to syngeneic diabetic rats.
Topics: Animals; B-Lymphocytes; Diabetes Mellitus, Experimental; Guanidines; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Proinsulin; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Thiazoles; Transplantation, Isogeneic | 2000 |
Age breakers. Rupturing the body's sugar-protein bonds might turn back the clock.
Topics: Aging; Carbohydrate Metabolism; Collagen; Elasticity; Glycation End Products, Advanced; Humans; Proteins; Thiazoles | 2000 |
A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys.
Topics: Aging; Animals; Arteries; Blood Pressure; Echocardiography; Glycation End Products, Advanced; Heart Rate; Hemodynamics; Injections, Intramuscular; Macaca mulatta; Male; Muscle, Smooth, Vascular; Pulse; Stroke Volume; Thiazoles; Time Factors; Ventricular Function, Left | 2001 |
Clinical trial to pharmacologically reverse the effects of ageing and diabetes.
Topics: Aging; Clinical Trials, Phase II as Topic; Diabetes Mellitus; Double-Blind Method; Female; Glycation End Products, Advanced; Humans; Male; Middle Aged; Multicenter Studies as Topic; Thiazoles | 2000 |
Glucose-mediated cross-linking of collagen in rat tendon and skin.
Topics: Animals; Calorimetry, Differential Scanning; Collagen; Cross-Linking Reagents; Glucose; Male; Protein Structure, Secondary; Rats; Rats, Wistar; Sensitivity and Specificity; Skin; Tail; Tendons; Thiazoles; Time Factors | 2002 |
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.
Topics: Animals; Blood Pressure; Body Weight; Collagen; Cytokines; Diabetes Mellitus, Experimental; Gene Expression Regulation; Glycation End Products, Advanced; Heart Ventricles; Hypertrophy, Left Ventricular; Immunohistochemistry; Male; Myocardium; Natriuretic Peptide, Brain; Organ Size; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Thiazoles | 2003 |
Getting better without AGE: new insights into the diabetic heart.
Topics: Animals; Collagen; Cytokines; Diabetes Mellitus, Experimental; Gene Expression Regulation; Glycation End Products, Advanced; Heart Ventricles; Hypertrophy, Left Ventricular; Natriuretic Peptide, Brain; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Thiazoles | 2003 |
Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart.
Topics: Aging; Animals; Blood Glucose; Collagen Type I; Collagen Type III; Cross-Linking Reagents; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Dogs; Glycation End Products, Advanced; Hemodynamics; Male; Myocardium; Solubility; Thiazoles | 2003 |
The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.
Topics: Albuminuria; Animal Population Groups; Animals; Blood Pressure; Collagen; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Glycation End Products, Advanced; Immediate-Early Proteins; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Kidney; Kinetics; Lysine; Models, Biological; Rats; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Solubility; Thiazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tyrosine | 2003 |
Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Cardiac Output; Cardiovascular System; Coronary Circulation; Dose-Response Relationship, Drug; Heart Rate; Heart Ventricles; Hydroxyproline; Kidney; Liver; Male; Models, Animal; Models, Cardiovascular; Rats; Rats, Inbred SHR; Regional Blood Flow; Thiazoles; Vascular Resistance | 2004 |
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.
Topics: Actins; Animals; Aorta; Arteriosclerosis; Collagen; Cytokines; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Glycation End Products, Advanced; Guanidines; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth; Oxidation-Reduction; Skin; Thiazoles | 2004 |
Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.
Topics: Actins; Animals; Apolipoproteins E; Blood Pressure; Body Weight; Collagen Type I; Collagen Type IV; Diabetic Nephropathies; Glycation End Products, Advanced; Kidney; Lipid Metabolism; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Organ Size; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Thiazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Extracellular Matrix Proteins; Glycation End Products, Advanced; Guanidines; Kidney Cortex; Male; Protein Kinase C; Protein Kinase C-alpha; Protein Transport; Rats; Rats, Sprague-Dawley; Thiazoles | 2004 |
The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Dose-Response Relationship, Drug; Glycation End Products, Advanced; Guanidines; Immunohistochemistry; Impotence, Vasculogenic; Male; Rats; Rats, Sprague-Dawley; Streptozocin; Thiazoles | 2006 |
Alagebrium: benefit on peripheral arteries.
Topics: Arteries; Cardiac Output, Low; Humans; Thiazoles | 2006 |
Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711).
Topics: Animals; Diabetic Nephropathies; Female; Glycation End Products, Advanced; Lysine; Mice; Mice, Mutant Strains; Thiazoles | 2006 |
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cytosol; Diabetes Mellitus, Experimental; Drug Synergism; Drug Therapy, Combination; Enzyme Activation; Glycation End Products, Advanced; Kidney; Lysine; Male; Mitochondria; NF-kappa B; Oxidative Stress; Protein Kinase C; Ramipril; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Renin-Angiotensin System; Superoxide Dismutase; Thiazoles; Vascular Endothelial Growth Factor A | 2007 |
Slowing arterial aging: how far have we progressed?
Topics: Aging; Blood Pressure; Glycation End Products, Advanced; Humans; Hypertension; Peripheral Vascular Diseases; Thiazoles | 2007 |
Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties.
Topics: Apolipoprotein A-I; Atherosclerosis; ATP-Binding Cassette Transporters; Biological Transport; CD11b Antigen; Cell Line; Cells, Cultured; Cholesterol; Electrophoresis, Polyacrylamide Gel; Glycation End Products, Advanced; Glycosylation; Guanidines; HeLa Cells; Humans; Lipid Metabolism; Lipoproteins, HDL; Phospholipids; Ribose; Thiazoles; Transfection | 2007 |
Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats.
Topics: Animals; Blood Glucose; Blotting, Western; Body Weight; Diabetes Mellitus, Experimental; Duodenum; Enteric Nervous System; Enzyme-Linked Immunosorbent Assay; Glycation End Products, Advanced; Guanidines; Immunohistochemistry; Male; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles | 2008 |
Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I.
Topics: Apolipoprotein A-I; Arginine; Cross-Linking Reagents; Glycosylation; Guanidines; Humans; Lipoproteins, HDL; Lysine; Metformin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyridoxamine; Pyruvaldehyde; Thiazoles; Tryptophan | 2008 |
Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Diet; Dietary Fats; Endomyocardial Fibrosis; Glycation End Products, Advanced; Immunohistochemistry; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocarditis; Oxidative Stress; Random Allocation; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; Superoxides; Thiazoles | 2008 |
Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines.
Topics: Aging; Animals; Aorta; Collagen; Dogs; Drug Evaluation, Preclinical; Elastin; Glycation End Products, Advanced; Heart Ventricles; Hypertension; Lysine; Muscle, Smooth, Vascular; Thiazoles; Vasa Vasorum; Vascular Resistance; Ventricular Function, Left | 2008 |
Letter by Hartog et al. regarding article, "Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines".
Topics: Animals; Arginine; Collagen; Cross-Linking Reagents; Dogs; Glycation End Products, Advanced; Hypertension; Lysine; Muscle, Smooth, Vascular; Thiazoles | 2009 |
Alagebrium chloride protects the heart against oxidative stress in aging rats.
Topics: Aging; Animals; DNA, Mitochondrial; Echocardiography; Female; Glutathione Peroxidase; Glycation End Products, Advanced; Heart; Myocardium; Oxidative Stress; Protective Agents; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Thiazoles | 2009 |
Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats.
Topics: Adipose Tissue; Animals; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Gene Expression Regulation; Glucose; Glucose Intolerance; Glucose Transporter Type 4; Insulin; Insulin Receptor Substrate Proteins; Male; Phosphorylation; Pyruvaldehyde; Rats; Rats, Sprague-Dawley; Thiazoles; Tyrosine | 2010 |
Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy.
Topics: Adenosine Triphosphate; Albuminuria; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diet; Disease Models, Animal; Disease Progression; Glycation End Products, Advanced; Glycolysis; Ion Channels; Kidney; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Mitochondrial Proteins; Oxidative Stress; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Superoxides; Thiazoles; Time Factors; Uncoupling Protein 2 | 2010 |
Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage.
Topics: Accommodation, Ocular; Animals; Anterior Eye Segment; Eye; Female; Glaucoma, Open-Angle; Glycation End Products, Advanced; Immunohistochemistry; Injections; Intraocular Pressure; Macaca mulatta; Microscopy, Electron; Optic Disk; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Refraction, Ocular; Retina; Thiazoles; Vitreous Body | 2009 |
Renoprotective antioxidant effect of alagebrium in experimental diabetes.
Topics: Acute Kidney Injury; Albuminuria; Animals; Antioxidants; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hydrogen Peroxide; Immunoenzyme Techniques; Male; Mesangial Cells; Mice; Mice, Inbred C57BL; NADPH Oxidases; Oxidative Stress; Protein Kinase C; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; RNA, Messenger; Thiazoles | 2011 |
The advanced glycation end product-lowering agent ALT-711 is a low-affinity inhibitor of thiamine diphosphokinase.
Topics: Animals; Binding Sites; Cattle; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Enzyme Assays; Glycation End Products, Advanced; Inhibitory Concentration 50; Kidney; Kinetics; Models, Molecular; Nucleoside-Diphosphate Kinase; Protein Kinase Inhibitors; Thiamine; Thiamine Pyrophosphate; Thiazoles | 2011 |
The AGE-breaker ALT-711 restores high blood flow-dependent remodeling in mesenteric resistance arteries in a rat model of type 2 diabetes.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Type 2; Endothelium, Vascular; Glycation End Products, Advanced; Male; Mesenteric Arteries; Rats; Rats, Zucker; Thiazoles; Vascular Resistance; Vasodilation | 2012 |
Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness.
Topics: Aging; Animals; Diastole; Drug Evaluation, Preclinical; Glycation End Products, Advanced; Hemodynamics; Male; Physical Conditioning, Animal; Rats; Rats, Inbred F344; Systole; Thiazoles; Vascular Stiffness; Ventricular Function, Left | 2012 |
Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice.
Topics: Albuminuria; Animals; Apolipoproteins E; Diabetes Mellitus, Experimental; Fibrosis; Glomerular Mesangium; Glomerulonephritis; Glycation End Products, Advanced; Male; Mice; Mice, Knockout; Nephritis; Oxidative Stress; Quinapril; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Tetrahydroisoquinolines; Thiazoles | 2012 |
Methylglyoxal, a reactive glucose metabolite, increases renin angiotensin aldosterone and blood pressure in male Sprague-Dawley rats.
Topics: Aldosterone; Angiotensins; Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Catecholamines; Cells, Cultured; Disease Models, Animal; Hypertension; Male; NF-kappa B; Pyruvaldehyde; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Renin; Renin-Angiotensin System; RNA Interference; RNA, Messenger; Signal Transduction; Thiazoles; Time Factors; Up-Regulation | 2014 |
AGE-breaker ALT-711 plus insulin could restore erectile function in streptozocin-induced type 1 diabetic rats.
Topics: Animals; Apoptosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Erectile Dysfunction; Hypoglycemic Agents; Insulin; Male; Malondialdehyde; Nitric Oxide Synthase Type I; Oxidative Stress; Penile Erection; Penis; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Thiazoles | 2014 |
Alagebrium (ALT-711) improves the anti-hypertensive efficacy of nifedipine in diabetic-hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Endothelin-1; Epoprostenol; Heart Rate; Hypertension; Male; Nifedipine; Nitric Oxide; Rats; Rats, Wistar; Thiazoles | 2014 |
The impracticality of biomedical rejuvenation therapies: translational and pharmacological barriers.
Topics: Aging; Biotechnology; Glycation End Products, Advanced; Humans; Lysosomes; Medication Adherence; Pharmacology; Polypharmacy; Rejuvenation; Telomere; Thiazoles; Translational Research, Biomedical | 2014 |
In vitro glycation of an endothelialized and innervated tissue-engineered skin to screen anti-AGE molecules.
Topics: Animals; Capillaries; Cattle; Cell Differentiation; Cells, Cultured; Collagen; Cytoskeleton; Dermis; Endothelial Cells; Fibroblasts; Filaggrin Proteins; Glycation End Products, Advanced; Glycosylation; Glyoxal; Guanidines; Humans; Keratinocytes; Lysine; Mice; Neurons; Protective Agents; Skin; Thiazoles; Tissue Engineering | 2015 |
Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats.
Topics: Animals; Aorta, Abdominal; Collagen; Diabetes Mellitus; Glycation End Products, Advanced; Graft Occlusion, Vascular; Male; Neointima; Obesity; Rats; Rats, Zucker; Receptor for Advanced Glycation End Products; Shear Strength; Stents; Stress, Mechanical; Thiazoles; Transforming Growth Factor beta; Vascular Resistance | 2015 |
Advanced glycation end-products induce skeletal muscle atrophy and dysfunction in diabetic mice via a RAGE-mediated, AMPK-down-regulated, Akt pathway.
Topics: Aged; AMP-Activated Protein Kinases; Animals; Atrophy; Case-Control Studies; Diabetes Mellitus; Diabetes Mellitus, Experimental; Down-Regulation; Glycation End Products, Advanced; Humans; Male; MAP Kinase Signaling System; Mice; Muscle Fatigue; Muscle Fibers, Skeletal; Muscle Proteins; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Receptor for Advanced Glycation End Products; Regeneration; Signal Transduction; SKP Cullin F-Box Protein Ligases; Thiazoles | 2016 |
Alagebrium attenuates methylglyoxal induced oxidative stress and AGE formation in H9C2 cardiac myocytes.
Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Cell Line; Cells, Cultured; Free Radical Scavengers; Glucose; Glycation End Products, Advanced; Myocytes, Cardiac; NF-kappa B; Oxidative Stress; Pyruvaldehyde; Rats; Reactive Oxygen Species; Receptor for Advanced Glycation End Products; Thiazoles | 2016 |
Matrix metalloproteinases are possible targets in monocrotaline-induced pulmonary hypertension: investigation of anti-remodeling effects of alagebrium and everolimus.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Everolimus; Hypertension, Pulmonary; Male; Matrix Metalloproteinases; Monocrotaline; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Thiazoles; Vasodilator Agents | 2017 |
Pharmacological evaluation of novel alagebrium analogs as methylglyoxal scavengers in vitro in cardiac myocytes and in vivo in SD rats.
Topics: Animals; Cells, Cultured; Drug Evaluation, Preclinical; Glycation End Products, Advanced; Male; Myocytes, Cardiac; Pyruvaldehyde; Rats; Rats, Sprague-Dawley; Thiazoles | 2016 |
Effect of Advanced Glycation End-Products (AGE) Lowering Drug ALT-711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKD-MBD.
Topics: Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Minerals; Pharmaceutical Preparations; Rats; Renal Insufficiency, Chronic; Thiazoles | 2020 |
Electrochemical Quantitation of Supramolecular Excipient@Drug Complexation: A General Assay Strategy Based on Competitive Host Binding with Surface-Immobilized Redox Guest.
Topics: Adamantane; Binding Sites; Bridged-Ring Compounds; Electrochemical Techniques; Ferrous Compounds; Imidazoles; Macromolecular Substances; Metallocenes; Molecular Structure; Oxidation-Reduction; Quaternary Ammonium Compounds; Surface Properties; Thiazoles | 2020 |
Effect of atorvastatin on AGEs-induced injury of cerebral cortex via inhibiting NADPH oxidase -NF-κB pathway in ApoE
Topics: Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Cerebral Cortex; Diet, High-Fat; Gene Expression Regulation; Glycation End Products, Advanced; Immunohistochemistry; Inflammation; Male; Mice; Mice, Knockout; NADPH Oxidases; Neurons; Oxidative Stress; Receptor for Advanced Glycation End Products; Signal Transduction; Thiazoles; Transcription Factor RelA | 2020 |
The therapeutic effect of ALT-711 on erectile function in rats treated with high-level AGEs (advanced glycation end products) containing diet.
Topics: Animals; Diabetes Mellitus, Experimental; Diet; Erectile Dysfunction; Glycation End Products, Advanced; Male; Nitric Oxide Synthase Type III; Penile Erection; Penis; Rats; Rats, Sprague-Dawley; Thiazoles | 2022 |